Back to CatalogSomatotropic research
A compelling paired formulation for researchers examining two distinct, complementary routes involved in growth-hormone signaling and downstream biomarker response.
Scientific overview
CJC-1295 is a long-acting growth-hormone-releasing hormone analog. Ipamorelin is a growth-hormone secretagogue studied primarily for selective activation of the ghrelin receptor. The combination is discussed in research markets, but the blend itself lacks robust controlled human efficacy trials.
Mechanism under study
The compounds approach growth-hormone signaling through different receptors: CJC-1295 through the GHRH receptor and ipamorelin through GHS-R1a. Mechanistic complementarity does not prove that a combined formulation is safe or clinically beneficial.
Evidence landscape
Human CJC-1295 pharmacology studies reported sustained GH and IGF-I signaling, while ipamorelin selectivity was characterized largely in animal models. Controlled human efficacy evidence for the combined formulation remains limited.
Research focus
Continue exploring